Results 151 to 160 of about 12,515 (211)

Successful Long-Term Control of the Syndrome of Episodic Angioedema With Eosinophilia (Gleich Syndrome) With Low-Dose Imatinib Mesylate and Prednisone. [PDF]

J Investig Med High Impact Case Rep, 2021
Butterfield JH.
europepmc   +1 more source

Imatinib mesylate: a novel immune suppressive agent? [PDF]

, 2004
Richard T. Maziarz
openalex   +1 more source

Safety outcomes of low versus high dose imatinib mesylate in patients with advanced, metastatic, or nonresectable gastrointestinal stromal tumors: A systematic review. [PDF]

Gastrointest Tract
Marucci MA, Lechner DW, Tafuto BA.
europepmc   +1 more source

Impact of Fas/Fasl Gene Polymorphisms on Susceptibility Risk and Imatinib Mesylate Treatment Response in Chronic Myeloid Leukaemia Patients. [PDF]

Asian Pac J Cancer Prev, 2021
Annuar AA, Ankathil R, Mohd Yunus N, Husin A, Ab Rajab NS, Abdul Aziz AA, Ibrahim MI, Sulong S.   +7 more
europepmc   +1 more source

A novel mechanism for imatinib mesylate (STI571) resistance in CML cell line KT-1: role of TC-PTP in modulating signals downstream from the BCR-ABL fusion protein [PDF]

, 2004
Takatsune Shimizu, Yoshitaka Miyakawa, Satoshi Iwata, Akiko Kuribara, Tony Tiganis, Chikao Morimoto, Yasuo Ikeda, Masahiro Kizaki   +7 more
openalex   +1 more source

A case-matched study of imatinib mesylate between different formulations on plasma trough concentration, adverse events, quality of life and outcomes in gastrointestinal stromal tumor patients. [PDF]

PLoS One
Zeng L, Cheng X, Li J, Zhang J, Wu X.
europepmc   +1 more source

The INVENT COVID trial: a structured protocol for a randomized controlled trial investigating the efficacy and safety of intravenous imatinib mesylate (Impentri®) in subjects with acute respiratory distress syndrome induced by COVID-19. [PDF]

Trials, 2022
Atmowihardjo L, Schippers JR, Bartelink IH, Bet PM, van Rein N, Purdy K, Cavalla D, Comberiati V, McElroy A, Snape SD, Bogaard HJ, Heunks L, Juffermans N, Schultz M, Tuinman PR, Bos LDJ, Aman J.   +16 more
europepmc   +1 more source

Imatinib mesylate (STI571) decreases the vascular endothelial growth factor plasma concentration in patients with chronic myeloid leukemia [PDF]

, 2004
Ludovic Legros
openalex   +1 more source

Imatinib mesylate induced erythroderma

Indian Journal of Dermatology, Venereology, and Leprology, 2012
Uday Khopkar, Swapnil A Sanghavi, Atul M Dongre   +2 more
openaire   +2 more sources

Fibroblast Growth Factor 2 (FGF2) Activates Vascular Endothelial Growth Factor (VEGF) Signaling in Gastrointestinal Stromal Tumors (GIST): An Autocrine Mechanism Contributing to Imatinib Mesylate (IM) Resistance. [PDF]

Cancers (Basel)
Boichuk S, Dunaev P, Galembikova A, Valeeva E.   +3 more
europepmc   +1 more source